A Phase 1, Open-label, Single-site, Randomized, Single-dose, Three-way, Crossover Study to Assess the Relative Bioavailability of BMS-986435 Tablet Formulations in Healthy Adult Participants
Latest Information Update: 18 Mar 2025
At a glance
- Drugs MYK 224 (Primary)
- Indications Heart failure; Hypertrophic cardiomyopathy
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 14 Mar 2025 Status changed from active, no longer recruiting to completed.
- 25 Nov 2024 Status changed from recruiting to active, no longer recruiting.
- 16 Oct 2024 Status changed from not yet recruiting to recruiting.